期刊
FREE RADICAL RESEARCH
卷 36, 期 4, 页码 455-460出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10715760290021315
关键词
amyotrophic lateral sclerosis; Parkinson's; Huntington's; free radicals
资金
- NIA NIH HHS [AG14390, AG12992] Funding Source: Medline
- NINDS NIH HHS [NS38180] Funding Source: Medline
Coenzyme Q(10) (CoQ(10)) is an essential cofactor of the electron transport gene as well as an important antioxidant, which is particularly effective within mitochondria. A number of prior studies have shown that it can exert efficacy in treating patients with known mitochondrial disorders. We investigated the potential usefulness of coenzyme Q(10) in animal models of Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD). It has been demonstrated that CoQ(10) can protect against striatal lesions produced by the mitochondrial toxins malonate and 3-nitroprop ionic acid. These toxins have been utilized to model the striatal pathology, which occurs in HD. It also protects against 1-methyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity in mice. CoQ(10) significantly extended survival in a transgenic mouse model of ALS. CoQ(10) can significantly extend survival, delay motor deficits and delay weight loss and attenuate the development of striatal atrophy in a transgenic mouse model of HD. In this mouse model, it showed additive efficacy when combined with the N-methyl-D-aspartate (NMDA) receptor antagonist, remacemide. CoQ(10) is presently being studied as a potential treatment for early PD as well as in combination with remacemide as a potential treatment for HD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据